Updates

October 26, 2020October 27, 2020
Adding Ibrance to Hormone Therapy Fails to Prolong Time Before Cancer Recurs, Trial Shows

Adding Ibrance (palbociclib) to standard endocrine therapy failed to prolong the time women with early hormone receptor (HR)-positive, human epidermal growth factor (HER2)-negative breast ... Read more
October 22, 2020October 22, 2020
COVID-19 Surgery Delays May Mean 2,700 More Breast Cancer Deaths Within 10 Years

Delays in breast cancer surgery due to the COVID-19 pandemic could cost 2,797 additional deaths in the U.S. over the next decade, according ... Read more
October 19, 2020October 19, 2020
Signatera Test for Residual Disease Will Be Used in New Phase 2 Breast Cancer Trial

Signatera, Natera’s personalized test to detect residual signs of cancer in people with solid tumors, will be used in an upcoming Phase 2 trial as ... Read more
October 15, 2020October 15, 2020
Trodelvy Shows Superiority to Chemo for Advanced TNBC in Phase 3 Trial

Trodelvy (sacituzumab govitecan), compared with standard chemotherapy, significantly prolonged overall survival and improved the overall response rate of patients with metastatic triple-negative breast cancer (mTNBC) ... Read more
October 12, 2020October 12, 2020
MammaCare Foundation Offers Simulator Training for Manual Breast Exams

The MammaCare Foundation is offering a simulator to help train healthcare professionals and students in performing manual breast exams, with the aim of improving an ... Read more

Subscribe to our mailing list

Get regular updates delivered to your email box.

Thanks! Please check your email for a confirmation email.

June 22, 2018June 22, 2018

Clinical Trial of Tamoxifen-based Gel in Reducing Breast Density Recruiting in US, EU

News

The ability of a gel containing a tamoxifen-byproduct to reduce breast density — associated with an increased risk of breast cancer — is now being evaluated in a recruiting Phase 3 clinical trial. Approximately half of women in ... Read more

Adding Ibrance to Hormone Therapy Fails to Prolong Time Before Cancer Recurs, Trial Shows

COVID-19 Surgery Delays May Mean 2,700 More Breast Cancer Deaths Within 10 Years

Signatera Test for Residual Disease Will Be Used in New Phase 2 Breast Cancer Trial

Trodelvy Shows Superiority to Chemo for Advanced TNBC in Phase 3 Trial

MammaCare Foundation Offers Simulator Training for Manual Breast Exams

FDA Puts Eganelisib on Fast Track for Advanced Triple-negative Breast Cancer

Activities Abound for Breast Cancer Awareness Month

Verzenio With Endocrine Therapy Can Lower Risk of Recurrence, Spread in Early Breast Cancer, Trial Shows

Clinical Trial Testing Estrogen Receptor Degrader GDC-9545 Enrolls First Participant

Phase 1 Trial Begins Dosing Patients With Investigational Brain-penetrant HER2 Inhibitor

TTC-352 Safe for Patients Resistant to Hormone Therapy, Phase 1 Trial Finds

Subscribe to our mailing list

First Patient Dosed in IRENE Trial Testing Immunotherapy-Oncolytic Virus Combo

Tesetaxel With Reduced-dose Capecitabine Improved Progression-free Survival in Metastatic Breast Cancer

FDA Reviewing Oral Paclitaxel Combo as Metastatic Breast Cancer Treatment

Phase 2 Trial Launched to Test CFI-400945 Plus Imfinzi in Advanced TNBC

Tecentriq-Chemotherapy Combo Falls Short in TNBC Phase 3 IMpassion131 Trial

EU Approves Piqray-Faslodex Combo for Certain Advanced Breast Cancer With PIK3CA Mutation

Tukysa Combo Approved in Australia for Advanced HER2-Positive Breast Cancer

FDA Will Review Two New Applications Seeking Keytruda Approval for TNBC

Fewer, Higher Doses of Radiation Therapy Safe for Early Breast Cancer

Devyser’s Gene Screening Test for Breast, Ovarian Cancers Approved in Europe

EU Certifies Software That Assesses Short-term Breast Cancer Risk

Trodelvy Better Than Chemo at Prolonging Survival in Advanced TNBC, Trial Shows

Diet Rich in Fiber Linked to Lower Breast Cancer Risk, Pooled Data Show

EMA Grants Trastuzumab Deruxtecan Accelerated Assessment for Advanced HER2-positive Breast Cancer

Tecentriq-Chemo Combo Ups Percentage of TNBC Patients With No Cancer at Surgery

FDA Approves Phesgo as Injection Treatment for HER2-positive Breast Cancers

FDA’s New ‘Project Patient Voice’ to Share Symptoms Data From Cancer Trials

Cancer Vaccine Combo to be Tested in Triple Negative Breast Cancer

Pre-Surgical Imfinzi Combo Increases Cancer Eradication Chances in Trial

Ibrance Plus Endrocrine Therapy Unlikely to Stop Cancer Spread, Committee Says

Merck to Launch Ontruzant, a Herceptin Biosimilar, in US

Kisqali Prolongs Overall Survival in Advanced Breast Cancer Patients with Internal Organ Metastases

3 Levels of Care Recommended for Breast Cancer Patients During COVID-19 Pandemic

Gene Signature Can Predict Breast Cancer Responsiveness to New Class of Drugs, Scientists Say

Tukysa Approved as Combo Therapy for Metastatic HER2-positive Breast Cancer in Switzerland

FDA Approves Tukysa for Advanced HER2-positive Breast Cancer

Enhertu Approved for HER2-Positive Inoperable or Metastatic Cancer in Japan

Industry leaders seek to advance innovative resources for rare and orphan disease communities amid COVID-19 outbreak

Surge in Telemedicine One ‘Good’ Outcome from COVID-19 Crisis, Doctors Say

Trodelvy Approved for Heavily Pre-treated TNBC Patients in US

Concure’s New $2.5M Funding to Boost Patient Access to its Radioactive Seed Treatment